TSE:4568Pharmaceuticals
Daiichi Sankyo (TSE:4568) Valuation After Patent Win and New ENHERTU, DATROWAY Oncology Milestones
Daiichi Sankyo Company (TSE:4568) has just cleared a major legal hurdle while pushing deeper into oncology, with a U.S. appeals court invalidating a Seagen patent and fresh clinical momentum around ENHERTU and DATROWAY.
See our latest analysis for Daiichi Sankyo Company.
The mix of a cleared patent overhang and steady ENHERTU and DATROWAY news flow has not yet turned the tide. The share price has delivered a year-to-date return of negative 19.3 percent and a one-year total shareholder return...